News | November 17, 2025
AstraZeneca and Sun Pharma partner to expand hyperkalemia treatment in India
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) is indicated for the treatment of hyperkalaemia in adult patients
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
AstraZeneca Pharma India discontinues manufacturing of Imdur
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Subscribe To Our Newsletter & Stay Updated
